BSX

Hashdex and Tidal Announce Approval for Listing U.S. Spot Bitcoin ETF

Retrieved on: 
Thursday, January 11, 2024

Following conversion of the Hashdex Bitcoin Futures ETF, newly named Hashdex Bitcoin ETF (DEFI) to offer U.S. investors exposure to spot Bitcoin prices

Key Points: 
  • Following conversion of the Hashdex Bitcoin Futures ETF, newly named Hashdex Bitcoin ETF (DEFI) to offer U.S. investors exposure to spot Bitcoin prices
    New York / Rio de Janeiro / London, January 10, 2024 – Hashdex , a leading global crypto-focused asset manager, and Tidal Investments LLC (Tidal), a leading name in the ETF industry, today announced approval of its listing rule to convert the Hashdex Bitcoin Futures ETF, currently traded on the New York Stock Exchange (“NYSE”) under the ticker DEFI, to the Hashdex Bitcoin ETF, which will offer spot Bitcoin exposure to U.S. investors.
  • “Today’s announcement marks the next phase for the industry by allowing U.S. investors to fully participate in the promise of Bitcoin,” said Marcelo Sampaio, Co-Founder and CEO of Hashdex.
  • Unlike other spot price ETFs that are newly formed, upon completion, the conversion of DEFI will provide investors with immediate exposure to spot bitcoin prices through a trusted and proven product already being traded in the U.S.
    “Bitcoin’s time has arrived, and Hashdex and Tidal are proud to offer the Hashdex Bitcoin ETF at this pivotal moment in history,” said Samir Kerbage, CIO at Hashdex.
  • “The Hashdex Bitcoin ETF has been custom-built to offer investor protections that are unavailable when trading Bitcoin directly in unregulated markets,” said Mike Venuto, CIO and Co-Founder of Tidal.

AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX

Retrieved on: 
Wednesday, January 10, 2024

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Axonics, Inc. (NasdaqGS: AXNX) to Boston Scientific Corporation (NYSE: BSX).
  • Under the terms of the proposed transaction, shareholders of Axonics will receive $71.00 in cash for each share of Axonics that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)

Retrieved on: 
Monday, January 8, 2024

BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Ambrx will be acquired by Johnson & Johnson (“J&J”) (NYSE – JNJ).
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

Retrieved on: 
Monday, January 8, 2024

Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.

Key Points: 
  • Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
  • Axonics brings a complementary product portfolio to the Boston Scientific Urology business.
  • Upon completion of the transaction, Axonics will become a wholly owned subsidiary of Boston Scientific.
  • J.P. Morgan Securities LLC is serving as financial advisor and K&L Gates LLP is serving as legal counsel to Axonics.

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

Retrieved on: 
Monday, January 8, 2024

“Revenue grew 27% in 4Q23 and 34% in FY23, driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts.

Key Points: 
  • “Revenue grew 27% in 4Q23 and 34% in FY23, driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts.
  • In 2023, our team is humbled and gratified that clinicians used Axonics therapies to treat approximately 100,000 incontinence patients globally.”
    The preliminary revenue results below are unaudited and remain subject to adjustment.
  • Total company net revenue is expected to be approximately $366.1 million, an increase of 34% compared to fiscal year 2022.
  • Sacral neuromodulation revenue is expected to be approximately $291.7 million, an increase of 31% compared to fiscal year 2022.

Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results

Retrieved on: 
Friday, January 5, 2024

MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m.

Key Points: 
  • MARLBOROUGH, Mass., Jan. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023, on Wednesday, January 31, 2024, at 8:00 a.m.
  • The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer.
  • The company will issue a news release announcing financial results for the fourth quarter on January 31 prior to the conference call.
  • A live webcast and replay of the webcast will be accessible at https://investors.bostonscientific.com.

NACD New England honors Waters Corp. and Devoted Health as Public and Private Company “Boards of the Year”

Retrieved on: 
Monday, December 18, 2023

The boards of directors of Waters Corp. (NYSE: WAT) and Devoted Health are being honored as, respectively, the Public and Private Company Boards of the Year.

Key Points: 
  • The boards of directors of Waters Corp. (NYSE: WAT) and Devoted Health are being honored as, respectively, the Public and Private Company Boards of the Year.
  • Waters , based in Milford, Mass., is a global leader in analytical instruments and software for the life, materials, food, and environmental sciences.
  • Devoted Health , of Waltham, Mass., is an all-in-one healthcare company for Medicare beneficiaries, delivering health insurance, access to high quality medical care, and a world-class service experience.
  • He also serves on the boards of Stonehill College and the New England Council and several advisory boards.

Butterfield Announces Share Repurchase Program

Retrieved on: 
Tuesday, December 5, 2023

Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced that its Board of Directors has approved a $90 million ordinary share repurchase program (“the Share Repurchase Program”) pursuant to which the Bank is authorized to purchase up to 3.5 million of its ordinary shares through December 31, 2024.

Key Points: 
  • Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced that its Board of Directors has approved a $90 million ordinary share repurchase program (“the Share Repurchase Program”) pursuant to which the Bank is authorized to purchase up to 3.5 million of its ordinary shares through December 31, 2024.
  • Michael Collins, Chairman and Chief Executive Officer said: “I am pleased that the Board of Directors has approved a new Share Repurchase Program as the Bank continues to produce significant capital by generating strong risk adjusted returns.
  • Repurchases under the new Share Repurchase Program may be made in the open market or through privately negotiated transactions, including under US Securities & Exchange Commission Rule 10b5-1, and will be made in accordance with applicable laws and regulations.
  • The Share Repurchase Program will come into effect on December 15, 2023 with the termination of the current 3.0 million share repurchase program that was announced on February 13, 2023.

Miami International Holdings Announces New MIAX Sapphire Options Trading Floor to be Located in Wynwood District of Miami; 38,400 Square Foot Facility will Include Office Space for MIAX Employees and Market Participants

Retrieved on: 
Monday, December 4, 2023

The new MIAX Sapphire exchange will be MIAX's fourth national securities exchange for U.S. multi-listed options and will operate both an electronic exchange and physical trading floor.

Key Points: 
  • The new MIAX Sapphire exchange will be MIAX's fourth national securities exchange for U.S. multi-listed options and will operate both an electronic exchange and physical trading floor.
  • The MIAX Sapphire trading floor will be the first national securities exchange to establish operations in Miami, Florida, and will include a next-generation trading floor, ancillary office space for MIAX employees and market participants, conference facilities and broadcast media space.
  • We look forward to continued collaboration with the fast-growing Miami financial community as we expand MIAX's presence in the city."
  • We are proud to have supported MIAX's expansion in Miami and will continue to partner with them as they engage with our community."

Miami International Holdings Announces New MIAX Sapphire Options Trading Floor to be Located in Wynwood District of Miami; 38,400 Square Foot Facility will Include Office Space for MIAX Employees and Market Participants

Retrieved on: 
Monday, December 4, 2023

The new MIAX Sapphire exchange will be MIAX's fourth national securities exchange for U.S. multi-listed options and will operate both an electronic exchange and physical trading floor.

Key Points: 
  • The new MIAX Sapphire exchange will be MIAX's fourth national securities exchange for U.S. multi-listed options and will operate both an electronic exchange and physical trading floor.
  • The MIAX Sapphire trading floor will be the first national securities exchange to establish operations in Miami, Florida, and will include a next-generation trading floor, ancillary office space for MIAX employees and market participants, conference facilities and broadcast media space.
  • We look forward to continued collaboration with the fast-growing Miami financial community as we expand MIAX's presence in the city."
  • We are proud to have supported MIAX's expansion in Miami and will continue to partner with them as they engage with our community."